Skip to content
Triangle logo TriangleGet started
← Breast Cancer

HEALTH PROFESSIONAL · SOURCE READING

Postoperative therapy for HER2-positive breast cancer

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Systemic Therapy for Stages I, II, and III Breast Cancer / Stages I, II, and III HER2-Positive Breast Cancer

Patients who have not been treated with preoperative systemic therapy.

Standard treatment for HER2-positive early breast cancer is 1 year of adjuvant HER2-targeted therapy.

Continue within this section

Trastuzumab →Pertuzumab →Trastuzumab emtansine (T-DM1) →Neratinib →

Preserved source evidence · Not medical advice